Lisa Conte | President & Chief Executive Officer |
Carol Lizak | Senior Vice President, Finance & Chief Accounting Officer |
Ian Wendt | Vice President, Commercial Strategy |
Pravin Chaturvedi | Chief Scientific Officer |
Michael Guy | Vice President, Preclinical & Nonclinical Studies |
Steven King | Chief Sustainable Supply Ethnobotanical Research and IP Officer |
Peter Hodge | Senior Director of Investor Relations |
Good day and welcome to the Jaguar Health Investor Conference Call. Today's conference is being recorded.
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product and technology initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on current available information and management's current assumptions, expectations and projections about future events.